|Title:||Effect of liraglutide on physical performance in type 2 diabetes: Results of a randomized, double-blind, controlled trial (LIPER2)||Authors:||Wägner, A. M.
Miranda Calderín, Guillermo
Ugarte-Lopetegui, M. A.
López-Madrazo, M. J.
Alberiche-Ruano, M. P.
Abselam Ahmed, N.
Díez del Pino, A.
Nóvoa-Mogollón, F. J.
|UNESCO Clasification:||32 Ciencias médicas||Keywords:||Diabetes
Maximum oxygen consumption
Randomized controlled trial
|Issue Date:||2019||Publisher:||1262-3636||Journal:||Diabetes and Metabolism||Abstract:||Aims To assess the effect of the GLP-1 analogue liraglutide on measures of cardiac function and physical performance in patients with type 2 diabetes (T2D). Methods In this phase-IV randomized double-blind placebo-controlled parallel-group clinical trial at a tertiary hospital, T2D patients with HbA1c levels of 7–10% with oral agents and/or intermediate-/long-acting insulin were allocated (computer-generated randomization, ratio 1:1) to either liraglutide 1.8 mg/day or a placebo for 6 months. The primary endpoint was maximum oxygen consumption (VO2max) during cycle ergometry, while other procedures included a 6-min walk test, echocardiography, anthropometry and blood tests. Safety endpoints were also monitored, and an intention-to-treat analysis was performed. Results A total of 24 patients (15 women) aged 52 (11.7) years, with diabetes duration of 8.7 (5.8) years, BMI 34.98 (6.2) kg/m2 and HbA1c 8.2% (0.68%), were randomized to liraglutide 1.8 mg daily or placebo. There were no differences in VO2max [17.98 (4.8) vs. 15.90 (4.96) mL/kg/min; P > 0.10], VE/VCO2 slope [30.18 (4.8) vs. 32 (4.49)], left ventricular ejection fraction or 6-min walk test [530.7 (86) vs. 503.9 (84) m] at 6 months. HbA1c was lower (6.7% vs. 7.7%; P = 0.005), with a trend towards lower maximum systolic blood pressure during ergometry [171.7 (24.4) vs. 192.5 (25.6); P = 0.052] in the liraglutide group at the end of the study. There were no severe adverse events. Conclusion In this trial, liraglutide improved glycaemic control in T2D, but had no significant effects on either physical performance or myocardial function.||URI:||http://hdl.handle.net/10553/42367||ISSN:||1262-3636||DOI:||10.1016/j.diabet.2018.08.010||Source:||Diabetes & Metabolism[ISSN 1262-3636],v. 45 (3), p. 268-275, (Junio 2019)|
|Appears in Collections:||Artículos|
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.